Literature DB >> 28501593

Transmural ablation of the normal porcine common bile duct with catheter-directed irreversible electroporation is feasible and does not affect duct patency.

Eisuke Ueshima1, Mark Schattner2, Robin Mendelsohn2, Hans Gerdes2, Sebastien Monette3, Haruyuki Takaki4, Jeremy C Durack5, Stephen B Solomon5, Govindarajan Srimathveeravalli5.   

Abstract

BACKGROUND AND AIMS: The aim of this study was to evaluate the feasibility and early safety of catheter-directed irreversible electroporation (IRE) of the normal common bile duct (CBD) in swine.
METHODS: IRE (2000 V, 90 pulses, 100 μs pulse) was performed in the CBD of 6 Yorkshire pigs using a catheter electrode under endoscopic guidance. Ductal patency was assessed with immediate retrograde cholangiography and contrast-enhanced CT imaging at 1 or 7 days after treatment. Animals were killed at either 1 day (n = 4, 2 ablations/animal) or 7 days (n = 2, 1 ablation/animal) after treatment. The biliary tract was extracted en bloc and the length of the ablation along the CBD mucosa was measured. The depth of ablation was quantified using cross-sections of the treated CBD wall stained with hematoxylin and eosin. Single-sample hypothesis testing was performed to verify whether the depth of ablation in the CBD was a representative outcome of IRE treatment.
RESULTS: IRE of the CBD did not result in perforation or obstruction of the organ at 1 or 7 days after treatment. The length of ablation along the CBD mucosa was 17.27 ± 5.55 mm on day 1 samples, and transmural ablation of the CBD wall was a representative outcome of the treatment (7/8 samples, P < .05). Day 1 samples demonstrated loss of epithelium, transmural necrosis, with preservation of lumen integrity. Day 7 samples demonstrated re-epithelialization, with diffuse transmural fibrosis of the CBD wall. These findings were absent from sham tissue samples.
CONCLUSIONS: Intraluminal catheter-directed IRE is feasible and safe for full-thickness ablation of the normal porcine CBD without affecting lumen patency up to 1 week after treatment.
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28501593      PMCID: PMC5681441          DOI: 10.1016/j.gie.2017.05.004

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  9 in total

1.  Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction.

Authors:  Alan W Steel; Aymer J Postgate; Shirin Khorsandi; Joanna Nicholls; Long Jiao; Pangiotis Vlavianos; Nagy Habib; David Westaby
Journal:  Gastrointest Endosc       Date:  2011-01       Impact factor: 9.427

2.  Intraductal thermal injury using a heat probe and radiofrequency ablation electrode in a swine model of biliary stenosis.

Authors:  Jae Uk Shin; Kwang Hyuck Lee; Su-A Kim; Jong Hak Choi; Kwang Min Kim; Jong Kyun Lee; Kyu Taek Lee; Yoon-La Choi
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-06-15       Impact factor: 2.947

3.  Feasibility of catheter-directed intraluminal irreversible electroporation of porcine ureter and acute outcomes in response to increasing energy delivery.

Authors:  Govindarajan Srimathveeravalli; Mikhail Silk; Thomas Wimmer; Sebastien Monette; Simon Kimm; Majid Maybody; Stephen B Solomon; Jonathan Coleman; Jeremy C Durack
Journal:  J Vasc Interv Radiol       Date:  2015-03-11       Impact factor: 3.464

4.  Assessment of chronological effects of irreversible electroporation on hilar bile ducts in a porcine model.

Authors:  Jae Woong Choi; David S K Lu; Ferdnand Osuagwu; Steven Raman; Charles Lassman
Journal:  Cardiovasc Intervent Radiol       Date:  2013-11-07       Impact factor: 2.740

5.  Bile Duct Injury after Irreversible Electroporation of Hepatic Malignancies: Evaluation of MR Imaging Findings and Laboratory Values.

Authors:  Marco Dollinger; Florian Zeman; Christoph Niessen; Sven A Lang; Lukas P Beyer; Martina Müller; Christian Stroszczynski; Philipp Wiggermann
Journal:  J Vasc Interv Radiol       Date:  2016-01       Impact factor: 3.464

6.  Percutaneous ablation of peribiliary tumors with irreversible electroporation.

Authors:  Mikhail T Silk; Thomas Wimmer; Kyungmouk S Lee; Govindarajan Srimathveeravalli; Karren T Brown; Peter T Kingham; Yuman Fong; Jeremy C Durack; Constantinos T Sofocleous; Stephen B Solomon
Journal:  J Vasc Interv Radiol       Date:  2013-11-18       Impact factor: 3.464

7.  ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma.

Authors:  Daniel S Strand; Natalie D Cosgrove; James T Patrie; Dawn G Cox; Todd W Bauer; Reid B Adams; James A Mann; Bryan G Sauer; Vanessa M Shami; Andrew Y Wang
Journal:  Gastrointest Endosc       Date:  2014-05-15       Impact factor: 9.427

8.  Biliary tract perforation following percutaneous endobiliary radiofrequency ablation: A report of two cases.

Authors:  Chuanguo Zhou; Baojie Wei; Kun Gao; Renyou Zhai
Journal:  Oncol Lett       Date:  2016-04-14       Impact factor: 2.967

9.  Development of a Swine Benign Biliary Stricture Model Using Endoscopic Biliary Radiofrequency Ablation.

Authors:  Jin Seok Park; Seok Jeong; Joon Mee Kim; Sang Soon Park; Don Haeng Lee
Journal:  J Korean Med Sci       Date:  2016-09       Impact factor: 2.153

  9 in total
  3 in total

1.  Safety and efficacy of magnetic anchoring electrode-assisted irreversible electroporation for gastric tissue ablation.

Authors:  Fenggang Ren; Qingshan Li; Liangshuo Hu; Xiaopeng Yan; Zhongyang Gao; Jing Zhang; Weiman Gao; Zhe Zhang; Pengkang Chang; Xue Chen; Dake Chu; Rongqian Wu; Yi Lv
Journal:  Surg Endosc       Date:  2019-04-22       Impact factor: 4.584

2.  Evaluation of Alterations to Bile Ducts and Laboratory Values During the First 3 Months After Irreversible Electroporation of Malignant Hepatic Tumors.

Authors:  Wolf Bäumler; Mareike Sebald; Ingo Einspieler; Andreas Schicho; Jan Schaible; Philipp Wiggermann; Marco Dollinger; Christian Stroszczynski; Lukas Philipp Beyer
Journal:  Cancer Manag Res       Date:  2020-09-14       Impact factor: 3.989

Review 3.  Interventional Treatment for Cholangiocarcinoma.

Authors:  Hang Li; Li Chen; Guang-Yu Zhu; Xijuan Yao; Rui Dong; Jin-He Guo
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.